Southlake, Texas, April 24, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that its European Patent Office Application EP3834729 has been granted.

德克萨斯州南湖，2024年4月24日（环球通讯社）--心脏测试实验室（Heart Test Laboratories，Inc.）d/b/a HeartSciences（纳斯达克：HSCS；HSCSW）（“HeartSciences”或“公司”），一家以人工智能（AI）为动力的医疗技术公司，专注于通过早期检测心脏病来转化心电图/心电图以挽救生命，今天宣布其欧洲专利局申请EP3834729已获得批准。

Diastolic dysfunction (impaired cardiac relaxation) is a sensitive and crucial indicator of overall heart health, providing one of the earliest signs of heart disease, with onset typically occurring before symptoms. Diastolic dysfunction is caused by all common issues that affect heart function or that produce hypertrophy.

舒张功能障碍（心脏松弛受损）是整体心脏健康的敏感和关键指标，是心脏病的最早征兆之一，通常在症状出现之前发作。舒张功能障碍是由影响心脏功能或产生肥大的所有常见问题引起的。

All patients with heart disease have diastolic dysfunction, in contrast to systolic dysfunction (reduced pumping of blood by the heart or reduced ejection fraction), which only affects a subset of patients and typically occurs at a more severe, often symptomatic, stage of heart disease. Today, measures of diastolic function of the heart need to be assessed in a specialist cardiology environment, typically using echocardiography-based imaging.

与收缩功能障碍（心脏泵血减少或射血分数降低）相反，所有心脏病患者都有舒张功能障碍，收缩功能障碍仅影响一部分患者，通常发生在心脏病的更严重（通常是症状性）阶段。今天，心脏舒张功能的测量需要在专业的心脏病学环境中进行评估，通常使用基于超声心动图的成像。

The ability to assess cardiac diastolic function using an ECG makes it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “We are pleased to receive this latest patent grant which further reinforces our position at the forefront of AI-ECG.

使用心电图评估心脏舒张功能的能力使其成为更有价值的心脏筛查工具，特别是在一线或护理点临床环境中。心脏科学（HeartSciences）首席执行官安德鲁·辛普森（AndrewSimpson）评论道：“我们很高兴收到这项最新的专利授权，这进一步巩固了我们在AI-ECG领域的领先地位。

This patent is particularly valuable because it covers the use of AI-ECG to produce any echo measure of diastolic function, which is fundamental to screen for a broad range of heart disease at an early stage.” “Millions of ECGs are performed worldwide ev.

这项专利特别有价值，因为它涵盖了使用AI-ECG产生舒张功能的任何回声测量，这是早期筛查广泛心脏病的基础。”“全球范围内进行了数百万次心电图检查。